Igor I. Slukvin

Igor Slukvin


Pathology & Laboratory Medicine

News Releases:

More information:

  • Additional appointments: Cell & Regenerative Biology (joint appointment); Wisconsin National Primate Center (affiliate scientist)
  • Slukvin Laboratory Home Page

Organ System/Disease Focus: 

Blood development/disease

Aligned Research Focus: 

Hematopoietic and endothelial development from human pluripotent stem cells, hematopoietic stem cell (HSC) biology

Research Description: 

Pluripotent stem (PS) cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells, represent a unique population of cells capable of self-renewal and differentiation. Pluripotent stem cells can form any cell type in the body and serve as a scalable cell source for transplantation and tissue engineering. The main focus of my research is to establish the differentiation of human pluripotent stem cells into hematopoietic progenitors and mature blood cells in order to understand molecular mechanisms of early hematopoietic differentiation and provide a novel source of cells for bone marrow transplantation, transfusion and cancer immunotherapy. Recently we developed methods for efficient differentiation of PS cells into myelomonocytic and erythroid cells and identified the hierarchy of mesodermal and hematoendothelial progenitors leading to the formation of blood cells and hematopoiesis-supportive elements.  In addition, we developed technologies for efficient reprogramming of normal and neoplastic blood cells into iPS cells. Currently my laboratory is working on 1) identification of genes essential for acquisition of long-term engraftment potential by pluripotent stem cell-derived hematopoietic cells; 2) establishing non-human primate models of ES cell and iPS cell-based cellular therapy for blood and immune system disorders; 3) developing iPS cell based models for blood cancer stem cell development.

Selected References: 

  • Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee J, Tong L, Vodyanik M, Swanson S, Stewart R, Kyba M, Yakubov E, Cooke J, Thomson JA, and Slukvin II. Direct Induction of Hematoendothelial Program in Human Pluripotent Stem Cells by Transcriptional Regulators. Nat Commun. 2014 Jul 14;5:4372
  • Slukvin II. Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. Blood. 2013 Dec 12;122(25):4035-46.
  • Choi K., Vodyanik M, Togarrati P, Suknuntha K, Kumar A, Samarjeet F, Probasco M, Tian S, Stewart R, Thomson J, and Slukvin II Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell cultures. Cell rep. 2012 Sep 27;2(3):553-67.
  • Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi KD, Stewart R, Thomson JA, Slukvin II. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011 117(14):e109-119.
  • Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA, Slukvin II. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010 Dec 3;7(6):718-29


Blood Research Program